Hodgkin's Type of Richter's Syndrome in Familial Chronic Lymphocytic Leukemia Treated with Cladribine and Cyclophosphamide

Robak, Tadeusz; Szmigielska-Kapłon, Anna; Smolewski, Piotr; Wawrzyniak, Ewa; Korycka, Anna; Bartkowiak, Jacek; Kordek, Radzisław

doi:10.1080/1042819031000063417

Cited by 21 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical presentation and laboratory findings in the current series share some features with de novo Hodgkin lymphoma and are comparable to those from previously published series 1, 6, 7, 9, 17–25. However, the majority of those reports focused on the pathologic features of the disease.…”

Section: Discussionsupporting

confidence: 86%

Hodgkin transformation of chronic lymphocytic leukemia

Tsimberidou

O’Brien

Kantarjian

et al. 2006

Cancer

125

View full text Add to dashboard Cite

BACKGROUND Hodgkin transformation is a rare complication of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL/SLL who developed Hodgkin lymphoma (HL). METHODS An electronic database search of patients with CLL/SLL who presented at The University of Texas M. D. Anderson Cancer Center Department of Leukemia between 1975 and 2005 was performed. RESULTS Among 4121 patients with CLL/SLL, 18 patients (0.4%) developed HL. Presenting features included B‐symptoms (67%), lymph node enlargement (79%), splenomegaly (43%), hepatomegaly (29%), hypercalcemia (6%), infection (6%), and mental status changes (6%). The median age was 72 years (range, 49–81 years), and there was a male preponderance (78%). The median time from CLL to HL diagnosis was 4.6 years (range, 0–12.9 years). Fourteen patients (78%) had been previously treated for CLL/SLL. Ten patients (56%) had received >1 prior therapy. The median β2‐microglobulin level was 4.5 mg/L, and the median lactate dehydrogenase level was 610 IU/L. Epstein–Barr virus (EBV) was positive by in situ hybridization for EBV‐encoded RNA in 3 of 4 tested patients. Fourteen patients (78%) received chemotherapy. The overall response rate was 44% (complete response rate, 19%). The median overall survival duration was 0.8 years (range, 0.03 years–6.7+ years). The median failure‐free survival (FFS) duration was 0.4 years. CONCLUSIONS The rates of response, survival, and FFS in patients with Hodgkin transformation of CLL/SLL were inferior to those reported in patients with de novo HL and were similar to those in patients with Richter syndrome. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 86%

Hodgkin transformation of chronic lymphocytic leukemia

Tsimberidou

O’Brien

Kantarjian

et al. 2006

Cancer

125

View full text Add to dashboard Cite

show abstract

“…The patients with Hodgkin‐RT comprised five men and one woman with a median age of 70·6 years (range 55·8–76·3). One patient was reported earlier (Robak et al , ). All patients received cladribine‐based regimens before transformation, namely five patients received CC (cladribine and cyclophosphamide) and one patient received RCC (CC plus rituximab).…”

Section: Comparison Of Presenting Characteristics and Outcome Of Patimentioning

confidence: 83%

Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine

Jamroziak

Grzybowska–Izydorczyk

Jesionek-Kupnicka

et al. 2012

Br J Haematol

Self Cite

View full text Add to dashboard Cite

“…Nucleoside analogs such as fludarabine, 28,29 pentostatin, 30 and cladribine 31,32 have been combined effectively with CY in lymphoid malignancies such as CLL. Clinical data in patients who failed single-agent therapies with either nucleoside analogs or alkylating agents demonstrate that these patients can respond to the combination of such agents with an overall response rate of roughly 40%, 33 suggesting that the combination may lower or eliminate resistance to each agent when used individually.…”

Section: Discussionmentioning

confidence: 99%